VOYAGER THERAPEUTICS INC (VYGR) Fundamental Analysis & Valuation

NASDAQ:VYGR • US92915B1061

3.9 USD
-0.03 (-0.76%)
At close: Mar 6, 2026
3.96 USD
+0.06 (+1.54%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VYGR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall VYGR gets a fundamental rating of 2 out of 10. We evaluated VYGR against 520 industry peers in the Biotechnology industry. While VYGR has a great health rating, there are worries on its profitability. VYGR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. VYGR Profitability Analysis

1.1 Basic Checks

  • VYGR had negative earnings in the past year.
  • In the past year VYGR has reported a negative cash flow from operations.
  • In multiple years VYGR reported negative net income over the last 5 years.
  • VYGR had negative operating cash flow in 4 of the past 5 years.
VYGR Yearly Net Income VS EBIT VS OCF VS FCFVYGR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • VYGR has a Return On Assets (-43.81%) which is in line with its industry peers.
  • VYGR has a better Return On Equity (-57.45%) than 60.19% of its industry peers.
Industry RankSector Rank
ROA -43.81%
ROE -57.45%
ROIC N/A
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
VYGR Yearly ROA, ROE, ROICVYGR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VYGR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYGR Yearly Profit, Operating, Gross MarginsVYGR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. VYGR Health Analysis

2.1 Basic Checks

  • VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VYGR has more shares outstanding
  • The number of shares outstanding for VYGR has been increased compared to 5 years ago.
  • There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VYGR Yearly Shares OutstandingVYGR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
VYGR Yearly Total Debt VS Total AssetsVYGR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -0.84, we must say that VYGR is in the distress zone and has some risk of bankruptcy.
  • VYGR's Altman-Z score of -0.84 is in line compared to the rest of the industry. VYGR outperforms 56.15% of its industry peers.
  • There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.84
ROIC/WACCN/A
WACC8.79%
VYGR Yearly LT Debt VS Equity VS FCFVYGR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 6.19 indicates that VYGR has no problem at all paying its short term obligations.
  • VYGR has a better Current ratio (6.19) than 63.46% of its industry peers.
  • VYGR has a Quick Ratio of 6.19. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of VYGR (6.19) is better than 64.62% of its industry peers.
Industry RankSector Rank
Current Ratio 6.19
Quick Ratio 6.19
VYGR Yearly Current Assets VS Current LiabilitesVYGR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. VYGR Growth Analysis

3.1 Past

  • The earnings per share for VYGR have decreased strongly by -404.23% in the last year.
  • VYGR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.88%.
  • Measured over the past years, VYGR shows a decrease in Revenue. The Revenue has been decreasing by -5.18% on average per year.
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%

3.2 Future

  • The Earnings Per Share is expected to decrease by -6.88% on average over the next years.
  • The Revenue is expected to decrease by -8.25% on average over the next years.
EPS Next Y-88.71%
EPS Next 2Y-20.23%
EPS Next 3Y-8.08%
EPS Next 5Y-6.88%
Revenue Next Year-60.65%
Revenue Next 2Y-17.78%
Revenue Next 3Y-6.68%
Revenue Next 5Y-8.25%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
VYGR Yearly Revenue VS EstimatesVYGR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
VYGR Yearly EPS VS EstimatesVYGR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. VYGR Valuation Analysis

4.1 Price/Earnings Ratio

  • VYGR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year VYGR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VYGR Price Earnings VS Forward Price EarningsVYGR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VYGR Per share dataVYGR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • VYGR's earnings are expected to decrease with -8.08% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.23%
EPS Next 3Y-8.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VYGR Dividend Analysis

5.1 Amount

  • VYGR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VYGR Fundamentals: All Metrics, Ratios and Statistics

VOYAGER THERAPEUTICS INC

NASDAQ:VYGR (3/6/2026, 8:00:02 PM)

After market: 3.96 +0.06 (+1.54%)

3.9

-0.03 (-0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-10
Inst Owners65.12%
Inst Owner Change12.3%
Ins Owners1.09%
Ins Owner Change1.31%
Market Cap216.84M
Revenue(TTM)31.32M
Net Income(TTM)-126.30M
Analysts87.78
Price Target15.3 (292.31%)
Short Float %7.2%
Short Ratio5.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.56%
Min EPS beat(2)-6.33%
Max EPS beat(2)11.46%
EPS beat(4)1
Avg EPS beat(4)-17.11%
Min EPS beat(4)-57.86%
Max EPS beat(4)11.46%
EPS beat(8)5
Avg EPS beat(8)79.25%
EPS beat(12)8
Avg EPS beat(12)75.9%
EPS beat(16)10
Avg EPS beat(16)73.9%
Revenue beat(2)1
Avg Revenue beat(2)9.1%
Min Revenue beat(2)-48.55%
Max Revenue beat(2)66.75%
Revenue beat(4)1
Avg Revenue beat(4)-24.46%
Min Revenue beat(4)-62.87%
Max Revenue beat(4)66.75%
Revenue beat(8)5
Avg Revenue beat(8)80.35%
Revenue beat(12)8
Avg Revenue beat(12)85.04%
Revenue beat(16)10
Avg Revenue beat(16)78%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)18.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.92
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)-2.16
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-2.13
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS0.56
BVpS3.95
TBVpS3.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.81%
ROE -57.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.72%
Cap/Sales 6.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.19
Quick Ratio 6.19
Altman-Z -0.84
F-Score2
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)62.66%
Cap/Depr(5y)107.17%
Cap/Sales(3y)3.93%
Cap/Sales(5y)4.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
EPS Next Y-88.71%
EPS Next 2Y-20.23%
EPS Next 3Y-8.08%
EPS Next 5Y-6.88%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
Revenue Next Year-60.65%
Revenue Next 2Y-17.78%
Revenue Next 3Y-6.68%
Revenue Next 5Y-8.25%
EBIT growth 1Y-1300.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.78%
EBIT Next 3Y-14.55%
EBIT Next 5Y-12.11%
FCF growth 1Y-237.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-230.08%
OCF growth 3YN/A
OCF growth 5YN/A

VOYAGER THERAPEUTICS INC / VYGR FAQ

What is the fundamental rating for VYGR stock?

ChartMill assigns a fundamental rating of 2 / 10 to VYGR.


What is the valuation status of VOYAGER THERAPEUTICS INC (VYGR) stock?

ChartMill assigns a valuation rating of 0 / 10 to VOYAGER THERAPEUTICS INC (VYGR). This can be considered as Overvalued.


What is the profitability of VYGR stock?

VOYAGER THERAPEUTICS INC (VYGR) has a profitability rating of 1 / 10.


Can you provide the financial health for VYGR stock?

The financial health rating of VOYAGER THERAPEUTICS INC (VYGR) is 7 / 10.


Can you provide the expected EPS growth for VYGR stock?

The Earnings per Share (EPS) of VOYAGER THERAPEUTICS INC (VYGR) is expected to decline by -88.71% in the next year.